To the Editor: Dec and Fuster (Dec. 8 issue)1 categorized the use of beta-blockers in patients with idiopathic dilated cardiomyopathy as investigational. There is now sufficient evidence to support their use as adjunctive therapy. Numerous clinical trials have evaluated the use of beta-blockers in conjunction with angiotensin-converting—enzyme inhibitors, nitrates, diuretics, and digoxin in patients with idiopathic dilated cardiomyopathy and have found improvements in ejection fraction, cardiac index, and New York Heart Association class and a decreased number of hospital admissions and cardiac transplantations.2—4 However, there have been trials5,6 that did not show such improvements. This is probably because.
ASJC Scopus subject areas